Obinutuzumab - Biologic Drug Details

Summary for obinutuzumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for obinutuzumab

Recent Clinical Trials for obinutuzumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE2
Mario Negri Institute for Pharmacological Research	PHASE2
Li Zhiming	PHASE2

See all obinutuzumab clinical trials

Pharmacology for obinutuzumab

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for obinutuzumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for obinutuzumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,035,848	2035-01-08	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,092,569	2035-02-20	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,159,675	2036-12-01	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for obinutuzumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,035,848	2035-01-08	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,092,569	2035-02-20	Patent claims search
Genentech, Inc.	GAZYVA	obinutuzumab	Injection	125486	10,159,675	2036-12-01	Patent claims search

International Patents for obinutuzumab

Country	Patent Number	Estimated Expiration
Canada	2936346
European Patent Office	3092252
World Intellectual Property Organization (WIPO)	2015105973

Supplementary Protection Certificates for obinutuzumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1590071-5	Sweden		PRODUCT NAME: OBINUTUZUMAB; REG. NO/DATE: EU/1/14/937 20140724
2016/009	Ireland		PRODUCT NAME: OBINUTUZUMAB; NAT REGISTRATION NO/DATE: EU/1/14/937/001 20140723; FIRST REGISTRATION NO/DATE: IRELAND EU/1/14/937/001, 23/07/2014
C 2016 006	Romania		PRODUCT NAME: OBINUTUZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/14/937; DATE OF NATIONAL AUTHORISATION: EU/1/14/937; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): DATA NOTIFICARII 24.07.2014 EU/1/14/937; DATE OF FIRST AUTHORISATION IN EEA: 20140723

Obinutuzumab Market Dynamics and Financial Trajectory (Roche/Genentech): Sales, Drivers, Competition, and Patent/Biosimilar Outlook

Last updated: May 11, 2026

Obinutuzumab’s commercial trajectory is defined by (1) OS-focused positioning in B-cell malignancies, (2) narrowing funnel from standard-of-care shifts in CLL and FL, and (3) biosimilar and loss-of-exclusivity timing. The near-term market outlook depends on how clinicians sequence obinutuzumab against rituximab biosimilars and newer regimens, not on incremental label expansion alone.

What is obinutuzumab and where does it compete in the market?

Obinutuzumab (Gazyva, Roche/Genentech) is an anti-CD20 monoclonal antibody used across follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) via transplant strategies, and chronic lymphocytic leukemia (CLL).

Which indications drive revenue exposure?

Revenue concentration typically follows the largest addressable populations and protocol density:

• FL (including maintenance): higher regimen duration and repeat dosing.
• CLL (frontline and subsequent lines depending on region and protocol): high patient volume but increasing competitive pressure from newer targeted combinations and rituximab biosimilar substitution.
• DLBCL (transplant/conditioning-linked strategies): narrower, regimen-dependent.

How does obinutuzumab position versus rituximab biologics and biosimilars?

• Obinutuzumab is a “next-generation” anti-CD20 with differential binding and clinical outcomes versus rituximab in specific trials and settings.
• In practice, clinicians often choose obinutuzumab where it is embedded in guideline-supported protocols or where incremental benefit is expected to outweigh cost and regimen complexity.
• As rituximab biosimilars commoditize, payers increasingly treat anti-CD20 selection as cost-sensitive unless a protocol mandates obinutuzumab.

How do market dynamics affect obinutuzumab pricing and payer behavior?

Is obinutuzumab subject to biosimilar-driven price compression?

Yes. Even when obinutuzumab itself has not broadly faced “direct” biosimilar competition in all geographies, the anti-CD20 market has:

• multiple rituximab biosimilars,
• ongoing substitution pressure in infusion oncology,
• payer step edits and tendering in hospital procurement.

What is the economic impact of tendering and formulary placement?

• Hospitals increasingly use multi-manufacturer contracts for anti-CD20 antibodies.
• Procurement strategies favor therapies with lower net pricing or preferred formulary status.
• Obinutuzumab’s net price tends to be pressured when competitors have biosimilar availability or when physicians can meet regimen targets with alternatives at lower cost.

How does regimen design change uptake?

Uptake is sensitive to:

• combinations with chemotherapy versus targeted agents,
• sequencing after relapse,
• local protocol updates that incorporate newer agents,
• feasibility of infusion schedules and patient selection.

What is the financial trajectory of obinutuzumab (sales trend and margin drivers)?

Sales trend mechanics

Obinutuzumab’s sales trajectory is shaped by three common forces:

1. Utilization drift: shifts from guideline-standard regimens to newer targeted combinations can reduce the share of patients receiving anti-CD20 antibodies in specific lines.
2. Discounting and rebates: payer pressure intensifies as biosimilar competition accelerates in anti-CD20 class products.
3. Lifecycle dynamics: label breadth helps sustain volumes, but pricing pressure and competition can reduce revenue per treated patient.

What companies influence the financial trajectory?

• Roche/Genentech supply chain and portfolio mix: obinutuzumab performance is evaluated against Roche’s broader oncology pipeline.
• Competitive set: rituximab biosimilars and next-line oncology regimens that reduce the need for anti-CD20 backbone therapy.

(A precise, year-by-year sales table requires Roche’s reported segment disclosure by geography and product line. This dataset is not contained in the prompt.)

When does obinutuzumab lose exclusivity and what does the timeline imply for revenue?

How does exclusivity interact with biosimilar risk?

Loss of patent exclusivity drives biosimilar entry risk, which then drives:

• formulary switching,
• tender price drops,
• utilization migration to lower-cost versions.

Key timeline framework (what matters commercially)

• Patent expiry and any patent term adjustments by jurisdiction.
• Data exclusivity timing that affects regulatory approval.
• Settlement or co-existence agreements that delay launch.
• Switching dynamics: adoption often accelerates after biosimilar availability once payers and procurement cycles update.

(A jurisdiction-by-jurisdiction expiration schedule requires specific patent numbers and legal status.)

What patents protect obinutuzumab and how strong is the patent estate?

What types of patents typically matter for obinutuzumab?

A full patent estate assessment usually includes:

• composition of matter (antibody and variants),
• manufacturing process and purification claims,
• formulation and presentation (concentration, buffer, excipients, container/closure),
• method-of-use claims (indications, dosing schedules, combinations).

How does method-of-use protection affect competition?

Even after composition claims expire, method-of-use protection can:

• limit “automatic” biosimilar switching in some protocols,
• keep obinutuzumab protected for specific clinical use patterns.

How manufacturing patents block biosimilar launches

Manufacturing process claims can increase litigation leverage by:

• creating grounds to delay entry through infringement defenses,
• forcing settlement or design-around approaches.

(A complete strength assessment needs an inventory of relevant patent documents and their expiration/INPADOC status.)

Are there biosimilar or generic entry risks for obinutuzumab?

What is the biosimilar pathway risk profile?

For complex biologics like anti-CD20 antibodies, biosimilar risk is driven by:

• analytical comparability,
• clinical bridging requirements,
• formulation and glycosylation comparability,
• immunogenicity and interchangeability expectations by region.

Why anti-CD20 switching can happen quickly

Once approved and priced competitively:

• clinicians may switch for formulary compliance,
• payers can implement step therapy or mandatory selection within hospital networks,
• procurement cycles can convert volumes rapidly after launch.

Why switching may be slower in practice

Switching can lag due to:

• physician practice patterns and perceived efficacy/safety consistency,
• hospital pharmacy policies,
• patient-level considerations and prior-treatment response.

What patent litigation affects obinutuzumab market access?

Biosimilar and generic market access for biologics is often shaped by:

• litigation around composition and formulation claims,
• paragraph IV-style equivalents in biologics context (e.g., patent lists and disputes under the relevant regulatory framework),
• settlement agreements that specify:
  • launch dates,
  • territory carve-outs,
  • shared market mechanisms or coexistence terms.

(No litigation docket identifiers or settlement dates are provided in the prompt.)

What is the Orange Book status of obinutuzumab?

Obinutuzumab is a biologic and is not listed in the FDA’s Orange Book in the same manner as small-molecule drugs. For biologics, the practical reference is the FDA biologics licensing/related patent listings framework tied to product approval rather than an Orange Book entry.

(A specific FDA listing and patent list IDs are required to state status accurately.)

How does obinutuzumab compare with other anti-CD20 products in market outcomes?

Comparison against rituximab biosimilars

• Rituximab biosimilars exert broad cost pressure across anti-CD20 class.
• Obinutuzumab holds usage where clinical endpoints in certain protocols support it.
• Over time, class commoditization tends to shrink payer willingness to pay a premium unless a strong regimen-specific requirement exists.

Comparison against newer non-anti-CD20 regimens

• Novel targeted regimens in CLL and parts of lymphoma can reduce the role of CD20 backbone therapy.
• Market share shifts can occur as first-line and later-line standards evolve.

How do manufacturing and supply dynamics affect obinutuzumab commercialization?

What supply factors influence revenue?

• production scale and batch release timelines,
• cold-chain logistics for oncology infusions,
• distribution arrangements in major hospital clusters.

How supply constraints reshape contracting

When supply is constrained:

• pharmacies may prioritize high-volume protocol needs,
• payers may tighten approvals to specific indications,
• wholesalers adjust allocation and contract terms.

(No supply interruption events or plant-level details are provided in the prompt.)

What generic launch scenarios exist for biosimilars of obinutuzumab, and what barriers remain?

Launch scenario 1: early biosimilar entry after exclusivity

• fastest revenue impact via formulary switching,
• aggressive tender pricing,
• rapid volume conversion at hospital level.

Launch scenario 2: delayed entry via litigation/settlement

• delayed competitive pressure,
• longer period for Roche/Genentech to optimize contracting and utilization,
• potential for incremental label uptake to offset pricing declines.

Launch scenario 3: limited launch (narrow geography or narrow presentations)

• incremental competitive risk,
• slower market share erosion,
• continued premium pricing in protected clusters.

Key barriers that determine how disruptive entry becomes

• unresolved infringement scope for manufacturing/formulation claims,
• interchangeability expectations by region,
• negotiated procurement rules.

Which geographic markets are most exposed to pricing and volume pressure?

Exposure is typically highest where:

• biosimilar procurement is mature,
• tendering dominates hospital buying,
• payer policies are cost-minimization driven.

Exposure is usually lower where:

• protocol mandates obinutuzumab for specific regimens,
• biosimilar penetration is limited by regulatory delays or litigation.

(A country-by-country assessment requires regulatory approval status and patent lists per jurisdiction.)

Key Takeaways

• Obinutuzumab’s commercial performance is most sensitive to anti-CD20 class pricing pressure, especially from rituximab biosimilars, and to protocol sequencing shifts in CLL and lymphoma.
• Revenue trajectory is shaped by the interaction between patent/exclusivity timelines, biosimilar entry timing, and payer procurement cycles.
• The magnitude and speed of revenue erosion depend less on label breadth and more on switching mechanics: tendering, formulary placement, and litigation-driven launch delays.

FAQs

1. How quickly do hospitals switch from branded anti-CD20 antibodies to lower-cost biosimilars after approval?
2. What payer rules most influence obinutuzumab utilization in follicular lymphoma maintenance?
3. How does CLL treatment sequencing change the anti-CD20 backbone demand for obinutuzumab?
4. What claim types most often extend protection for monoclonal antibodies like obinutuzumab?
5. How do biosimilar launch settlements typically structure entry timing for biologic competitors?

References

1. FDA. “Biologics License Application (BLA) and biosimilar regulatory pathways.” U.S. Food and Drug Administration website.
2. EMA. “Guideline on similar biological medicinal products.” European Medicines Agency.